Postmenopausal hormones and coronary artery disease: Potential benefits and risks

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 21-26

  Lobo, R A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Coronary artery disease; Estrogen; Menopause; Progestogen

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; STATIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; WOMEN'S HEALTH;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HOT FLASHES; HUMANS; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOMEN'S HEALTH;

EID: 34548847208     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701578631     Document Type: Conference Paper

References (28)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
3. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-62
4. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001-8
5. Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 2001;38:1-7
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
7. Mikkola TS, Clarkson TB, Notelovitz M. Postmenopausal hormone therapy before and after the Women's Health Initiative study: what consequences? Ann Med 2004;36:402-13
8. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
9. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40
10. Hodis HN, Mack WJ, Zen SP, et al. for the Women's Estrogen-progestin Lipid Lowering Hormone Atherosclerosis Regression Trial Research Group. N Engl J Med 2003;349:535-46
11. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7
12. Hwang J, Mack WJ, Xiang M, et al. Long-term effect of estrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT). Atherosclerosis 2005;181:375-80
13. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement study (HERS). Circulation 2002;105:2962-7
14. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-14
15. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-99
16. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44
17. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. A prospective, observational study. Ann Intern Med 2001;135:1-8
18. Lobo RA, Pickar JH. Evaluation of cardiovascular-event rates with hormone replacement therapy in healthy postmenopausal women. Obstet Gynecol 2003;101:95S
19. Hsia J, Barad D, Margolis K, et al. Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (The Women's Health Initiative). Am J Cardiol 2003;92:264-9
20. Salpeter SR, Walsh JM, Greyber E, et al. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-6
21. Atsma F, Bartelink MLEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-79
22. Mack WJ, Slater CC, Xiang M, et al. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004;82:391-7
23. Joakimsen O, Bonaa KH, Stensland-Bugge E, et al. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis - The Tromso Study. J Clin Epidemiol 2000;53:525-30
24. Lokkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006;53:226-33
25. Dubey RK, Imthurn B, Barton M, et al. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306
26. Walsh M, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243-52
27. Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl JMed 2006;355:125-37
28. Ridker PM, Cannon CP, Morrow D, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304